All Posts
ASA Consensus Guidance | Preoperative management of patients on GLP-1 agonists
5 Jul, 2023 | 01:17h | UTCCommentary: Anesthesiologists Say Ozempic, Wegovy Should Be Halted Prior to Surgery – HealthDay
RCT | Opioids not more effective than placebo for acute low back and neck pain
5 Jul, 2023 | 01:15h | UTCOpioid analgesia for acute low back pain and neck pain (the OPAL trial): a randomised placebo-controlled trial – The Lancet (link to abstract – $ for full-text)
News Releases:
Opioids no more effective than placebo for acute back and neck pain – University of Sidney
Opioid pain relievers do not reduce acute lower back and neck pain, study suggests – The Lancet
Commentary from the authors: Opioids don’t relieve acute low back or neck pain – and can result in worse pain, new study finds – The Conversation
RCT | Transcranial direct current stimulation fails to outperform sham in major depressive disorder treatment
5 Jul, 2023 | 01:12h | UTCTranscranial direct current stimulation as an additional treatment to selective serotonin reuptake inhibitors in adults with major depressive disorder in Germany (DepressionDC): a triple-blind, randomised, sham-controlled, multicentre trial – The Lancet (link to abstract – $ for full-text)
RCT | No statistically significant impact of vitamin D on major cardiovascular events
5 Jul, 2023 | 01:11h | UTCRelated:
2ry analysis of a RCT | Vitamin D supplementation does not affect cognitive function in older adults
Randomized Trial: Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease
Meta-Analysis: Vitamin D Not Effective for Cardiovascular Disease Prevention
Vitamin D, calcium, other vitamins, and supplements do not prevent cardiovascular diseases
RCT | Lower rates of treatment failure with standard-course vs. short-course therapy in pediatric UTIs
5 Jul, 2023 | 01:09h | UTCShort-Course Therapy for Urinary Tract Infections in Children: The SCOUT Randomized Clinical Trial – JAMA Pediatrics (link to abstract – $ for full-text)
See also: Visual Abstract
Commentary: Treatment Failure Down With Standard-Course Therapy in Pediatric UTI – HealthDay
Review | Pathogenesis and management of abdominal aortic aneurysm
5 Jul, 2023 | 01:07h | UTCPathogenesis and management of abdominal aortic aneurysm – European Heart Journal
See also: Visual Abstract
RCT | Effect of mifepristone vs. placebo for treatment of adenomyosis with pain symptoms
5 Jul, 2023 | 01:06h | UTCSee also: Visual Abstract
GRADE guidance 36: updates to GRADE’s approach to addressing inconsistency
5 Jul, 2023 | 01:05h | UTC
SR | Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
5 Jul, 2023 | 01:04h | UTC
RCT | FOLFOXIRI-Bevacizumab shows promise as first-line treatment in unresectable colorectal cancer metastases
5 Jul, 2023 | 01:02h | UTCFirst-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group – The Lancet Oncology (link to abstract – $ for full-tetxt)
M-A | Family screening for bicuspid aortic valve and aortic dilatation
5 Jul, 2023 | 01:01h | UTC
Commentary on Twitter
Family screening for bicuspid aortic valve and aortic dilatation: a meta-analysis https://t.co/8rc4Uysf5o @escardio #EHJ #ESCYoung pic.twitter.com/p4XRzb3mzb
— European Society of Cardiology Journals (@ESC_Journals) June 15, 2023
Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management
5 Jul, 2023 | 01:00h | UTC
2023 ESH Guidelines for the management of arterial hypertension
3 Jul, 2023 | 14:34h | UTC
RCT | Weekly insulin Icodec proves effective in glucose control in insulin-naive type 2 diabetes patients
3 Jul, 2023 | 14:32h | UTCSummary: The ONWARDS 3 randomized clinical trial studied the efficacy of once-weekly insulin icodec in comparison to once-daily insulin degludec for glucose control in insulin-naive type 2 diabetes patients. The double-masked, double-dummy trial was conducted from March 2021 to June 2022 across 92 sites in 11 countries, enrolling 588 adults with type 2 diabetes. The participants were randomly divided into two groups: 294 receiving once-weekly icodec and daily placebo, and 294 receiving daily degludec and weekly placebo.
The primary endpoint was the change in Hemoglobin A1c (HbA1c) from baseline to week 26. Insulin icodec showed a noninferior HbA1c change from the baseline (-1.6 percentage points) compared to insulin degludec (-1.4 percentage points) and demonstrated confirmed statistical superiority. However, the trial showed a higher rate of combined level 2 (clinically significant) or level 3 (severe) hypoglycemic events in the insulin icodec group than in the insulin degludec group, despite the overall low rates in both groups. There was no significant difference in weight changes between the two groups.
The study concluded that once-weekly insulin icodec demonstrated superior HbA1c reduction compared to once-daily degludec after 26 weeks of treatment in insulin-naive type 2 diabetes patients. The convenience of once-weekly administration should be considered against the slightly higher absolute risk of hypoglycemia. The study’s limitations include its short duration (26 weeks) and a lack of data on sustained effects, patient-reported outcomes, and continuous glucose monitoring.
Article: Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes: The ONWARDS 3 Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)
See also: Visual Abstract
Related Study: Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin – New England Journal of Medicine (link to abstract – $ for full-text)
Open-label RCT | Weekly insulin Icodec proves noninferior to daily Glargine in type 2 diabetes
3 Jul, 2023 | 14:23h | UTCWeekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin – New England Journal of Medicine (link to abstract – $ for full-text)
Related Study: Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes: The ONWARDS 3 Randomized Clinical Trial – JAMA (free for a limited period)
Scoping Review | High correlation of positive outcomes in oncology meta-analyses with industry funding
3 Jul, 2023 | 14:21h | UTC
M-A | Clinical tests for confirming tracheal intubation or excluding esophageal intubation
3 Jul, 2023 | 14:19h | UTC
M-A | Higher versus lower blood pressure targets after cardiac arrest
3 Jul, 2023 | 14:18h | UTC
Review | Respiratory challenges and ventilatory management in different types of acute brain-injured patients
3 Jul, 2023 | 14:17h | UTC
SR | Polyclonal anti‐thymocyte globulins for the prophylaxis of GVHD after allogeneic stem cell or bone marrow transplantation
3 Jul, 2023 | 14:16h | UTC
SR | Gonadotropin‐releasing hormone analogues for endometriosis
3 Jul, 2023 | 14:14h | UTCGonadotropin‐releasing hormone analogues for endometriosis – Cochrane Library
Summary: Gonadotrophin-releasing hormone analogues for pain associated with endometriosis – Cochrane Library
SR | Oral contraceptives containing drospirenone for premenstrual syndrome
3 Jul, 2023 | 14:13h | UTCOral contraceptives containing drospirenone for premenstrual syndrome – Cochrane Library
Summary: Birth control pills with drospirenone for treating premenstrual syndrome – Cochrane Library
USPSTF Recommendations | Screen for anxiety disorders in adults, including pregnant and postpartum women
30 Jun, 2023 | 15:03h | UTCEditorial: Are There Reasons to Fear Anxiety Screening? – JAMA
Evidence Report: Anxiety Screening: Evidence Report and Systematic Review for the US Preventive Services Task Force – JAMA
Patient Page: Screening for Anxiety Disorders in Adults – JAMA
Author Interview: USPSTF Recommendations: Screening for Depression and Suicide Risk in Adults, and Screening for Anxiety Disorders in Adults – JAMA
From NAFLD to MASLD | New consensus changes fatty liver disease terminology to avoid stigmatization
30 Jun, 2023 | 15:01h | UTCA multi-society Delphi consensus statement on new fatty liver disease nomenclature – Hepatology
Commentary on Twitter
Big news in the field of Hepatology
In 1980, Jurgen Ludwig and his colleagues at Mayo Clinic, identified a severe type of fatty liver disease in people who did not drink signficant amounts of alcohol. The disease was more common in women, most patients were obese and suffered… pic.twitter.com/aAq2vneIov
— TheLiverDoc (@theliverdr) June 25, 2023
Consensus Statement 2023 Update | Timing of elective surgery and risk assessment after SARS-CoV-2 infection
30 Jun, 2023 | 15:00h | UTCTiming of elective surgery and risk assessment after SARS-CoV-2 infection: 2023 update – Anaesthesia
Commentary on Twitter
?"In most circumstances, surgery should proceed unless risk assessment indicates that the risk of proceeding exceeds the risk of delay."@Assoc_Anaes @RCoANews @UkFssa @RCSnews @elboghdadly @doctimcook @justin_kua @NigelMercer @rmoonesinghe
?https://t.co/gfjymze0oi pic.twitter.com/D8bEfAHBD7
— ??????????? (@Anaes_Journal) June 20, 2023